SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...
At its ongoing genomics forum, narrow-moat Illumina finally gave investors a glimpse of its new product pipeline, which could help it stave off new entrants in its legacy sequencing business. While ...
SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic ...
At this year’s American Society of Human Genetics (ASHG) annual meeting, Illumina showcased its latest innovations designed to push the boundaries of genomic discovery and clinical research. Among ...
Aug 13 (Reuters) - Illumina (ILMN.O), opens new tab said on Tuesday it has partnered with the Broad Institute to develop new kits that will allow large-scale gene ...
Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback